PIPELINE

Promedior’s proprietary platform of pentraxin therapeutics is based upon breakthrough discoveries in how the body’s innate response to injury results in pathologic fibrosis and the loss of tissue and organ function. Promedior’s novel therapeutics are designed to treat and prevent fibrotic pathology by regulating the common cellular mechanisms that control the initiation and progression of fibrosis across a variety of tissues and organ systems.

Promedior’s initial drug products are based upon the unique structure of pentraxin-2, a naturally occurring protein which has demonstrated a unique role in targeting monocytes at sites of tissue damage. Promedior’s approach leverages the natural role of pentraxin-2 in regulating the response of important immune and inflammatory processes in the body.

Leveraging a strong R&D platform, Promedior has built a comprehensive patent estate for pentraxin-2 based therapeutics, including recombinant human pentraxin-2 (rhPTX-2 or human SAP), for a broad range of therapeutic applications in fibrosis and other inflammatory diseases.

PRM-151

Promedior’s lead product, PRM-151, is a recombinant form of human pentraxin-2 protein (rhPTX-2) formulated for intravenous or local injection. PRM-151 has demonstrated an outstanding safety profile in all toxicology studies and robust preclinical efficacy in multiple models of fibrotic disease. Promedior has demonstrated that PRM-151 dramatically reduces pulmonary fibrosis even when dosed therapeutically after established fibrosis is present, and significantly reduced scarring in a standard model of glaucoma filtration surgery. PRM-151 also significantly reduced pathologic neovascularization, a monocyte-controlled process, in two independent models of retinal disease. Highlights of PRM-151’s clinical development include:

• A Phase 1 clinical study of PRM-151 in healthy subjects and IPF patients was recently completed, demonstrating a strong safety profile and reductions in biomarkers associated with fibrotic disease progression.
• A Phase 2a study for the prevention of post-surgical scarring in glaucoma patients is currently underway.
• A Phase 1b multiple dose study in IPF patients is underway.

Intravitreal

Promedior is developing a proprietary formulation of Pentraxin-2 therapeutics for intravitreal delivery in retinal diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME).  Promedior has demonstrated robust preclinical efficacy of intravitreally delivered rhPTX-2 in choroidal neovascularization and retinal neovascularization models.  In these models rhPTX-2 potently inhibited both neovascularization and vascular leakage and these effects were associated with suppression of macrophage differentiation that drives harmful neovascularization, fibrosis and inflammation in AMD, DR and DME.

Inhaled

Promedior is developing a proprietary formulation of Pentraxin-2 therapeutics for self-administered inhaled delivery in diseases such as asthma and chronic obstructive pulmonary disease (COPD). Promedior has demonstrated robust preclinical efficacy of hPTX-2 in fungal induced asthma models following systemic or inhaled delivery. In these models hPTX-2 potently inhibited the M2 macrophage differentiation that drives harmful fibrosis and inflammation in asthma and COPD.

Subcutaneous

Promedior is developing a proprietary formulation of Pentraxin-2 therapeutics for delivery by self-administered subcutaneous injection in diseases such as chronic kidney disease. Promedior has demonstrated that hPTX-2 injections dramatically attenuated renal injury and fibrosis in multiple models of kidney disease.

rhPTX-2 Fusions

Promedior is leveraging its expertise in monocyte biology and fibrosis to develop Pentraxin-2 based derivative therapeutics that build on the targeting capabilities of pentraxins, which are known to specifically interact with key cells and signals at the site of injury.

[ back to top ]